AR038928A1 - Benzimidazol sulfonamidas sustituidas, como inhibidores de amplio espectro de la proteasa del vih - Google Patents
Benzimidazol sulfonamidas sustituidas, como inhibidores de amplio espectro de la proteasa del vihInfo
- Publication number
- AR038928A1 AR038928A1 ARP030100829A ARP030100829A AR038928A1 AR 038928 A1 AR038928 A1 AR 038928A1 AR P030100829 A ARP030100829 A AR P030100829A AR P030100829 A ARP030100829 A AR P030100829A AR 038928 A1 AR038928 A1 AR 038928A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het1
- het2
- aryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se reivindica compuestos, composición farmacéutica, método y uso. Reivindicación 1: Un compuesto que tiene la fórmula (1), o su N-óxido, sal, forma estereoisomérica, mezcla racémica, pro-droga, éster o metabolito del mismo, en la cual fórmula (1): R1 es hidrógeno, alquilo (C1-6), alquenilo (C2-6), arilalquilo (C1-6), aril-alquenilo (C2-6), cicloalquilo (C3-7), cicloalquilo(C3-7)-alquilo(C1-6), arilo, Het1, Het1-alquilo (C1-6), Het2, Het2-alquilo(C1-6); R1 también puede ser un radical de la fórmula (2), en la cual: R9, R10a y R10b son, cada uno de ellos e independientemente entre sí, hidrógeno, alquilo(C1-4)-alcoxicarbonilo, carboxilo, aminocarbonilo, mono- ó di-(alquilo C1-4)-aminocarbonilo, cicloalquilo (C3-7), alquenilo (C2-6), alquinilo (C2-6) ó alquilo (C1-4) opcionalmente sustituido por arilo, Het1, Het2, cicloalquilo (C3-7), alquilo(C1-4)-oxicarbonilo, carboxilo, aminocarbonilo, mono ó di(alquilo C1-4)aminocarbonilo, aminosulfonilo, alquilo(C1-4)S(O)t, hidroxi, ciano, halógeno u opcionalmente amino mono- o di-sustituido, siendo los sustituyentes seleccionados entre el grupo que consiste en: alquilo (C1-4), arilo, arilalquilo (C1-4), cicloalquilo (C3-7), cicloalquilo(C3-7)-alquilo(C1-4)alquilo, Het1, Het2, Het1-alquilo (C1-4) y Het2-alquilo (C1-4); en lo cual, R9, R10a y los átomos de carbono a los cuales están unidos, opcionalmente forman un radical cicloalquilo (C3-7); R11a es hidrógeno, alquenilo (C2-6), alquinilo (C2-6), cicloalquilo (C3-7), arilo, amino carbonilo opcionalmente mono o di- sustituido, amino-alquilo (C1-4)carboniloxi opcionalmente mono- o di-sustituido, ariloxicarbonilo, Het1-oxicarbonilo, Het2-oxicarbonilo, ariloxicarbonil-alquilo (C1-4), aril-alquilo (C1-4)oxicarbonilo, alquilo (C1-4)carbonilo, cicloalquilo(C3-7)carbonilo, cicloalquilo(C3-7)-alquilo(C1-4)oxicarbonilo, cicloalquilo(C3-7)alquilcarboniloxi, carboxil-alquilo (C1-4)carboniloxi, alquilo(C1-4)carboniloxi, arilalquilo(C1-4)carboniloxi, arilacarboniloxi, ariloxicarboniloxi, Het1-carbonilo, Het1-carboniloxi, Het1-alquilo(C1-4)xicarboniloxi, Het2-carboniloxi, Het2-alquil(C1-4)carboniloxi, Het2-alquilo(C1-4)carboniloxi ó alquilo (C1-4) opcionalmente sustituido por arilo, ariloxi, Het2 ó hidroxi, estando los sustituyentes opcionales en los grupos amino, cada uno de ellos e independientemente entre sí, seleccionados entre el grupo que consiste en:alquilo (C1-4), arilo, arilalquilo (C1-4), cicloalquilo (C3-7), cicloalquilo (C3-7)-alquilo (C1-4), Het1, Het2, Het1-alquilo (C1-4) y Het1-alquilo (C1-4); con lo cual R11a puede estar opcionalmente ligado al resto de la molécula por intermedios de un grupo sulfonilo; R11b es hidrógeno, cicloalquilo (C3-7), alquenilo (C2-6), alquinilo (C2-6), arilo, Het1, Het2 ó alquilo (C1-4) opcionalmente sustituido por halógeno, hidroxi, alquilo(C1-4)S(=O)t, arilo, cicloalquilo (C3-7),Het1, Het2, amino opcionalmente mono- o di- sustituido siendo los sustituyentes seleccionados entre el grupo que consiste en: alquilo (C1-4), arilo, arilo, aril-alquilo (C1-4), cicloalquilo (C3-7), cicloalquilo(C3-7)-alquilo(C1-4), Het1, Het2, Het1-alquilo (C1-4), y Het2-alquilo (C1-4); cada uno de los t, independientemente de los demás, vale 0, 1 R2 es hidrógeno ó alquilo (C1-6); L es -C(=O)-, -O-C(=O)-, -NR8-C(=O)-, -O-alcanodiilo(C1-6)-C(=O)-, -NR8-alcanodiilo(C1-6)-C(=O)-, -S(=O)2-, -O-S(=O)-2, -NR8-alcanodiilo(C1-6)-S(=O)2, con la cual sea el grupo C(=O) sea el grupo S(=O)2 está fijado a la parte NR2, con la cual sea la parte alconodiilo (C1-6) está opcionalmente sustituido por hidroxi, arilo, Het1 ó Het2; R3 es alquilo (C1-6), arilo, cicloalquilo (C3-7), cicloalquilo (C3-7)-alquilo(C1-4), ó arilalquilo (C1-4) opcionalmente sustituido por alquilo (C1-4), halógeno, nitro, ciano, poli halo alquilo (C1-4), hidroxi, alquilo (C1-4)oxi, mercapto ó alquilo (C1-4)tio; R4 es hidrógeno, alquilo (C1-4)oxicarbonilo, carboxilo, amino, carbonilo, mono- ó di-(alquilo C1-4)amino carbonilo, cicloalquilo (C3-7), alquenilo (C2-6), alquinilo (C2-6) ó alquilo (C1-4) opcionalmente sustituido por arilo, Het1, Het2, cicloalquilo (C3-7), alquilo(C1-4)oxicarbonilo, carboxilo, amino, carbonilo, mono- ó di-(alquiloC1-4)amino carbonilo, amino sulfonilo, alquilo(C1-4)S(=O)t, hidroxi, ciano, halógeno o amino mono- ó di- sustituido, siendo los sustituyentes seleccionados entre el grupo que consiste en: alquilo (C1-4), arilo, arilalquilo (C1-4), cicloalquilo (C3-7), cicloalquilo(C3-7)-alquilo(C1-4), Het1, Het2, Het1-alquilo (C1-4) y Het2-alquilo (C1-4); o R4 también puede ser -X-R7, en lo cual: X es -O- ó -N(R7)-Y-; Y es -C(=O)-, S(=O)2-, -O-C(=O)-, -NR8-C(=O)-, -C(=O)-C(=O)-, -O-S(=O)2- ó -Nt8(=O)2-; R5 es hidrógeno, hidroxi, alquilo (C1-6), Het1-alquilo (C1-6), Het2-alquilo (C1-6) amino-alquilo (C1-6), pudiendo el grupo amino estar opcionalmente mono- ó di- sustituido por alquilo (C1-4); R6 es hidrógeno, alquilo (C1-6)oxi, Het1, Het1-oxi, Het2, Het2-oxi, arilo, ariloxi, ariloxi-alquilo (C1-4), alquilo(C1-4)oxiarilo, alquilo (C1-4)oxi Het1, alquilo(C1-4)oxi Het2, alquilo(C1-4)oxicarbonilamino, amino(C1-4)amino, amino ó amino-alquilo(C1-4)oxi, y en el caso en que A no es alcanodiilo (C1-6), entonces R6 puede ser también alquilo (C1-6), Het1-alquilo (C1-4), Het1-oxi-alquilo (C1-4), Het2-alquilo (C1-4), Het2-oxi-alquilo (C1-4), ariloalquilo (C1-4), ariloxoxialquilo (C1-4) ó aminoalquilo (C1-4); pudiendo cada uno de los grupos amino estar mono- ó di- sustituido por alquilo (C1-4); R5 y -A-R6 tomados conjuntamente con el átomo de nitrógeno al cual están ligados, pueden también formar Het1 ó Het2; R7 es hidrógeno, arilo, cicloalquilo (C3-7), Het1, Het2, alquenilo (C2-6), alquinilo (C2-6), ó alquilo (C1-4) opcionalmente sustituido con arilo, Het1, Het2, cicloalquilo (C3-7), alquilo (C1-4)oxi carbonilo, carboxilo, aminocarbonilo, mono- ó di-(alquiloC1-4)aminocarbonilo, aminosulfonilo, alquilo(C1-4)S(=O)t, hidroxi, ciano, halógeno o amino opcionalmente mono- ó di- sustituido estando los sustituyentes seleccionados entre el grupo que consiste en: alquilo (C1-4), arilo arilalquilo (C1-4), cicloalquilo (C3-7), cicloalquilo(C3-7)-alquilo(C1-4), Het1, Het2, Het1 (C1-4) y Het2 (C1-4); R8 es hidrógeno, alquilo (C1-6), alquenil (C2-6), arilalquilo (C1-6), cicloalquilo (C3-7), cicloalquilo (C3-7)alquilo C(1-6), arilo, Het1, Het1 alquilo(C1-6), Het2 alquilo (C1-6) R12 es hidrógeno, -NH2, -alquilo (C1-6) ó -alquilo (C1-6)-W-R14, estando dicho alquilo (C1-6) opcionalmente sustituido por halógeno, hidroxi, arilo, heteroarilo, Het1, Het2, ó amino, estando dicho amino opcionalmente mono- ó di- sustituido por alquilo (C1-4) ; ó R12 también puede ser -(R5)(AR6), y A es alcanodiilo (C1-6), -C(=O)-, -C(=O)2-, alcanodiilo(C1-6)-C(O)-, alcanodiilo(C1-6)-C-(=S)-, ó alcanodiilo(C1-6)-S(=O)2-; en lo cual, si A es alcanodiilo(C1-6)-C(=O)-, alcanodiilo(C1-6)-C(=S)-, ó alcanodiilo(C1-6)-S(=O)2-, la parte NR5 está fijada a la parte alcanodiilo (C1-6); W es oxi,, carbonilo, oxicarboniolo, carboniloxi, oxicarboniloxi, amino, aminocarbonilo, carbonilamino ó azufre; R13 es hidrógeno, alquilo (C1-6), opcionalmente sustituido por arilo, Het1, Het2, hidroxi, halógeno, amino, pudiendo el grupo amino estar opcionalmente mono- ó di- sustituido por alquilo (C1-4); R14 es alquilo (C1-4), arilo, Het1 ó Het2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02075999 | 2002-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038928A1 true AR038928A1 (es) | 2005-02-02 |
Family
ID=27798870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100829A AR038928A1 (es) | 2002-03-12 | 2003-03-11 | Benzimidazol sulfonamidas sustituidas, como inhibidores de amplio espectro de la proteasa del vih |
Country Status (26)
Country | Link |
---|---|
US (2) | US20050171175A1 (es) |
EP (1) | EP1485358B1 (es) |
JP (1) | JP4557552B2 (es) |
KR (3) | KR20040093119A (es) |
CN (2) | CN101935303B (es) |
AP (1) | AP2111A (es) |
AR (1) | AR038928A1 (es) |
AT (1) | ATE497494T1 (es) |
AU (1) | AU2003219159B2 (es) |
BR (1) | BR0303373A (es) |
CA (1) | CA2479012C (es) |
DE (1) | DE60335939D1 (es) |
DK (1) | DK1485358T3 (es) |
EA (1) | EA011946B1 (es) |
HK (1) | HK1072053A1 (es) |
HR (1) | HRP20040936B1 (es) |
IL (1) | IL163960A0 (es) |
MX (1) | MXPA04008929A (es) |
MY (1) | MY142238A (es) |
NO (1) | NO326702B1 (es) |
NZ (1) | NZ535439A (es) |
PL (1) | PL213645B1 (es) |
SI (1) | SI1485358T1 (es) |
TW (1) | TWI329639B (es) |
WO (1) | WO2003076413A1 (es) |
ZA (1) | ZA200407242B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2537877C (en) * | 2003-09-30 | 2015-03-17 | Tibotec Pharmaceuticals Ltd. | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof |
CN1997363B (zh) * | 2004-05-07 | 2012-03-28 | 塞阔伊亚药品公司 | 抗耐药性反转录病毒蛋白酶抑制剂 |
MX2007010378A (es) | 2005-02-25 | 2007-09-25 | Tibotec Pharm Ltd | Sintesis del precursor inhibidor de la proteasa. |
UA103013C2 (uk) * | 2007-12-06 | 2013-09-10 | Тиботек Фармасьютикелз | Амідні сполуки як активатори противірусних препаратів |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
WO2013011485A1 (en) * | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5843946A (en) * | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
ATE174587T1 (de) | 1993-08-24 | 1999-01-15 | Searle & Co | Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
PT721331E (pt) | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
EP1586558A3 (en) * | 1995-01-20 | 2005-10-26 | G.D. Searle LLC. | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors |
US6140505A (en) * | 1995-03-10 | 2000-10-31 | G. D. Searle & Co. | Synthesis of benzo fused heterocyclic sulfonyl chlorides |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5776971A (en) * | 1995-03-10 | 1998-07-07 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
RU2174519C2 (ru) * | 1995-03-10 | 2001-10-10 | Джи. Ди. Сирл Энд Ко. | Гидроксиэтиламино сульфонамиды гетероциклокарбонил аминокислоты, ингибирующие ретровирусную протеазу |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
WO1997018205A1 (en) | 1995-11-15 | 1997-05-22 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
DK0904060T3 (da) | 1996-05-20 | 2004-04-13 | Janssen Pharmaceutica Nv | Antifungale præparater med forbedret biotilgængelighed |
PT969821E (pt) | 1997-03-26 | 2003-10-31 | Janssen Pharmaceutica Nv | Pastilhas tendo um nucleo revestido com um antifungico e um polimero |
WO1999006587A2 (en) * | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
AU2010299A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
AU2012199A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
AP2000001856A0 (en) | 1997-12-24 | 2000-09-30 | Vertex Pharma | Prodrugs of aspartyl protease inhibitors. |
EP1086076B1 (en) * | 1998-06-19 | 2004-12-22 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
-
2003
- 2003-03-10 MY MYPI20030825A patent/MY142238A/en unknown
- 2003-03-11 AR ARP030100829A patent/AR038928A1/es not_active Application Discontinuation
- 2003-03-11 TW TW092105142A patent/TWI329639B/zh not_active IP Right Cessation
- 2003-03-12 WO PCT/EP2003/050057 patent/WO2003076413A1/en active Application Filing
- 2003-03-12 AP APAP/P/2004/003151A patent/AP2111A/en active
- 2003-03-12 DE DE60335939T patent/DE60335939D1/de not_active Expired - Lifetime
- 2003-03-12 EA EA200401188A patent/EA011946B1/ru not_active IP Right Cessation
- 2003-03-12 AU AU2003219159A patent/AU2003219159B2/en not_active Ceased
- 2003-03-12 JP JP2003574633A patent/JP4557552B2/ja not_active Expired - Fee Related
- 2003-03-12 BR BR0303373-2A patent/BR0303373A/pt not_active IP Right Cessation
- 2003-03-12 CN CN201010251011.9A patent/CN101935303B/zh not_active Expired - Fee Related
- 2003-03-12 SI SI200331984T patent/SI1485358T1/sl unknown
- 2003-03-12 PL PL374152A patent/PL213645B1/pl unknown
- 2003-03-12 AT AT03714954T patent/ATE497494T1/de not_active IP Right Cessation
- 2003-03-12 EP EP03714954A patent/EP1485358B1/en not_active Expired - Lifetime
- 2003-03-12 CN CNA038104725A patent/CN1653053A/zh active Pending
- 2003-03-12 US US10/508,561 patent/US20050171175A1/en not_active Abandoned
- 2003-03-12 KR KR10-2004-7014171A patent/KR20040093119A/ko not_active Application Discontinuation
- 2003-03-12 IL IL16396003A patent/IL163960A0/xx unknown
- 2003-03-12 KR KR1020127028481A patent/KR20120136411A/ko not_active Application Discontinuation
- 2003-03-12 CA CA2479012A patent/CA2479012C/en not_active Expired - Fee Related
- 2003-03-12 NZ NZ535439A patent/NZ535439A/en not_active IP Right Cessation
- 2003-03-12 KR KR1020107018927A patent/KR101302421B1/ko not_active IP Right Cessation
- 2003-03-12 MX MXPA04008929A patent/MXPA04008929A/es active IP Right Grant
- 2003-03-12 DK DK03714954.9T patent/DK1485358T3/da active
- 2003-11-12 NO NO20035023A patent/NO326702B1/no not_active IP Right Cessation
-
2004
- 2004-09-09 ZA ZA2004/07242A patent/ZA200407242B/en unknown
- 2004-10-07 HR HRP20040936AA patent/HRP20040936B1/xx not_active IP Right Cessation
-
2005
- 2005-06-10 HK HK05104907.9A patent/HK1072053A1/xx not_active IP Right Cessation
-
2009
- 2009-04-27 US US12/430,547 patent/US8143421B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
AR038172A1 (es) | Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR076235A1 (es) | Compuestos organicos y sus usos | |
CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR075005A1 (es) | Derivados de sulfonamida | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
AR051642A1 (es) | Derivados de purina; un metodo para su preparacion; composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por el receptor a2a de adenosina. | |
CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
AR073922A1 (es) | 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
AR086086A1 (es) | Derivados glucosidos y usos de los mismos | |
AR060268A1 (es) | Tiazolil - dihidro - indazoles | |
AR035970A1 (es) | 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |